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Introduction
Naphthalimide and bisnaphthalimide are groups of aromatic 
compounds that have generated intense interests for a number of 
years by scientists around the world and this is due to their diverse 
applications in the medical and environmental sciences [1-3]. For 
example due to their inherent intense UV and fluorescence properties, 
the naphthalimido derivatives had been developed as highly selective 
fluoride ion sensors [4], molecular probes [5] and dyes [6]. However, 
the main application to date for the naphthalimides, is their potential 
as therapeutic agents [7] especially in the area of cancer therapy. The 
flat aromatic structural of the naphthalimido ring and its ability to 
bind to DNA by intercalation are attractive features that had attracted 
much attention in the development of new mono naphthalimides [8-
9] and bisnaphthalimido [10-11] derivatives for enhanced anticancer 
activities and aqueous solubility. Among the mononaphthalimido 
derivatives, Mitonafide and analogues had reached clinical trial but 
failed to progress due to unpredicted neurological toxicity side effects 
[12]. The first generation of mononaphthalmides developed by Brana et 
al. had a short linker chain from the naphthalimido ring with a tertiary 
amino group [1]. Since then other workers have made many changes 
to the naphthalimido rings especially with substitution at positions 5 
and 6. More recently Qian et al. have been working on 6 substituted 
naphthalimido derivatives and demonstrated that these compounds 
exhibited their toxicities due to a multi targets approach that involve 
inhibition of topoisomerase II and induction lysosomal membrane 
permeabilization leading eventually to apoptosis and cell death [13]. 
Here in this work we have focused our attention in the length of linker 
chains and the terminal groups. The linker alkyl chain was modified 
with 2, 3 and 4 carbons and the terminal groups include amino, imino, 
pyrrole, nitrobenzene, ureas. These compounds were screened against 
breast cancer MCF-7, colon cancer HCT-15 and pancreatic cancer 
BxPC-3 cell lines.
Results and Discussion
Chemistry
1,8-Naphtalimide compounds bearing 2,3 and 4 carbon chains, and 
different terminal functional groups were synthesized by methodologies 
based on well-established chemistry. Scheme 1 depicts the synthesis of 
naphthlimido alkylamine and alkyl alcohol products 1a-f in excellent 
yields. This was achieved by the reaction of naphthalic anhydride with 
corresponding diamines and amino alcohols in excess [14].
Scheme 1: Synthesis of naphthalimidoalkylamines 1a-c and 
naphthalimidoalkyl alcohols 1d-f: Amines 1a-c: 1,8-naphthalic 
anhydride, amine (2-6 equiv.), ethanol; 20 min-1 h, r.t.; Alcohols 
1d-f: 1,8-naphthalic anhydride, amino-alcohol (10 equiv.), DBU (1 
equiv.), 4-7 h, 75°C. Naphthalimidoalkylamines 1a-c were conjugated 
with a series of functional groups as shown in scheme 2, yielding 
compounds 2a-i, 4a-c, 5a-i and 6a-i. Reaction of the amines with 
heteroaromatic aldehydes occur by refluxing in ethanol furnishing 
the corresponding stable imines 2a-i. From the furan and thiophene 
imines derivatives (2f,g) bearing a three-carbon chain linking to 
naphthalimido group were reduced under NaBH4 to give the respective 
amines 3f,g. Subsequent hydrochloride salts were obtained by bubbling 
HCl gas through a solution of the amines in dichloromethane. 
The reactions of naphthalimidoalkylamines 1a-c with small excess 
of 2-methylisothiouronium iodide [15], gave guanidines 4a-c as 
the iodide salt in good yields. Reactions of 1a-c with cyclic or open 
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chain anhydrides gave amides 5a-l. Ureas 6a-l were obtained by the 
reaction of 1a-c with excess isocyanates under anhydrous atmosphere. 
Naphthalimidoalkyl 1,2,3-triazolo derivatives were obtained from the 
naphthamidoalkylalcohols 1d-f as depicted in Scheme 3. Briefly the 
hydroxyl group from 1d-f was functionalized into their respective 
bromides, 7d-f using carbon tetrabromide and triphenylphosphine. 
Subsequently these bromo intermediates were converted to the 
corresponding azides by Appel reaction. The azides 8d-f were submitted 
to click chemistry [16] conditions with phenylacetylene giving the 
corresponding 1,4-substituted 1,2,3-triazoles 9d-f.
Scheme 2- Synthesis of naphthalimidoalkyl derivatives 2a-i, 3f,g, 
4a-c, 5a-l, 6a-l Derivatives 2a-i : 1,8-naphthalimide 1a-c, aldehyde, 
ethanol; reflux for 20 min - 7 h; 61.7-100 %. Derivatives 3f,g: imine 2f,g, 
THF:MeOH, 1:1; NaBH4 (2 equiv.), r.t., 4-12 h; than HCl(g); 53.4-55.2%. 
Derivatives 4a-c: 1,8-naphthalimide 1a-c, 2-methylisothiouronium 
iodide (1.3 equiv.); r.t.; 74.1-89.2%, Derivatives 5a-l: 1,8-naphthalimide 
1a-c, anhydride (1.1-2.0 equiv.), ethanol or dichloromethane, reflux, 
1 h-2 h 30 min.; 54-87 %. Derivatives 6a-l: 1,8-naphthalimide 1a-c, 
dry toluene, isocyanate (1.0-2.5 equiv.), addition at 0°C, followed by 
refluxing at 130°C, 4-6 h; 55-98%.
Biological activity
Toxicity of the compounds to tumor cells: All the naphthalimido 
compounds described above were firstly screened for activity in a 
human breast tumor cell line (MDA-MB-231) at concentrations range 
of 0-40 µM using the MTT assay (data not shown). Compounds that 
presented potential as anticancer agents were further analyzed by the 
sulforhodamine B assay on three human tumor cell lines: MCF-7 (breast 
cancer), HCT-15 (colon cancer) and BxPC-3 (pancreatic cancer). 
Results are presented in (Table 1). The GI50 values were determined for 
the most active compounds, i.e. those showing ≥ 50% of cell growth 
inhibition in 5 µM concentration (Table 2). The breast cancer cell line 
MCF-7 showed to be more sensitive to the naphthalimidoethylamine 
1a (GI50 of 4.23 ± 0.50 µM), and to the urea 6f, which presented the 
lowest GI50 of all compounds tested (2.44 ± 0.25 µM). Concerning the 
other tumor cell lines HCT-15 and BxPC-3, the triazolo compound 9d 
(scheme 3) was the most active against HCT-15 (GI50 of 3.60 ± 0.25 
µM), whereas the guanidine compound 4a (scheme 2) was the most 
potent against BxPC-3. GI50 of compound 4a was not determined due 
to solubility limitation, but a 42.4 ± 1.6 % of cell growth inhibition in 
the presence of 5 µM of the compound suggested a GI50 value slightly 
over 5 µM. Results show means ± SE of at least three independent 
experiments performed in duplicate. NA: no activity shown. Structure-
activity relationship of the compounds against the three tumor 
cell lines showed that generally compounds with a 2 carbon linker 
(n=2) provided the best inhibition. The simplest compound, amine 
1a inhibited MCF-7 cell growth in a higher extend (62.4 ± 4.4 %), 
followed by triazole 9d (46.5 ± 5.9 % inhibition), imine 2c (45.5 ± 
12.1 % inhibition), guanidine 4a (29.0 ± 1.4 % inhibition), and urea 
6d (14.0 ± 5.9 % inhibition). In addition, the activity of 1a compound 
was lost when increasing the chain length from 2 to 3 carbon atoms 
(1b with 19.9 ± 3.3 % inhibition), suggesting that the shorter carbon 
chain (n=2) increase the effect of amine type 1 compounds against the 
MCF-7 cell line. For the colon cancer HCT-15 cell line, compound 9d 
bearing a 4-phenyl-1H-1,2,3-triazole unit showed higher activity (64.9 
± 7.7 % inhibition) than any other 2 carbon-atoms linker compounds. 
Again, the cellular growth inhibition was lost when the triazole group 
was combined with a 3 atoms carbon chain; inhibition with 9e is only 
8.2 ± 8.0 %. In the pancreatic cancer BxPC-3 cell line, the guanidine 
compound 4a showed to be the most active compound with 42.4 ± 
 
Scheme 1: Synthesis of naphthalimidoalkylamines.
Scheme 2: Synthesis of naphthalimidoalkyl derivatives.
 
 
Scheme 3: Synthesis of naphthalimidoalkyl 1H-1,2,3-triazoles 9d-f: i) 1,8-naph-
thalimidealkyl alcohols 1d-f, CBr4 (1.6 equiv.), PPh3 (1.6 equiv.), DCM, rt, 12-24 
h; 89-99%; ii) NaN3 (3 equiv.), dry DMF, rt, 3 d, 81-93 %; iii) phenylacetylene 
(1.3-1.5 equiv.), ascorbic acid (0.1 equiv.), CuSO4 (0.01 equiv.), DMF, 80°C, 
5-24 h, 53-95 %.
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1.6 % cell growth inhibition. Within the three types of tumor cell lines 
tested, BxPC-3 turned out to be the most sensitive to the compound 4a. 
Interestingly a different trend was observed with the ureas, in particular 
compound bearing a p-nitrophenyl group. Urea 6f bearing a 4 carbon 
atoms chain showed to be the most active compound against MCF-7 
cell line, displaying 84.5 ± 3.2 % inhibition of cellular growth. Shorter 
carbon chain resulted in the loss of activity particularly on MCF-
7 cell line; this is evident when comparing the inhibition activity of 
compounds 6f with 6e (n=3; 28.3 ± 4.1 %), and 6d (n=2; 14.0 ± 5.9 %). 
The nature of terminal groups in the urea compounds was also found to 
be important. This was evident when comparing the inhibitory activity 
of the three ureas 6f (84.5 ± 3.2 %), 6i (10.8 ± 0.6 %) and 6l (8.6 ± 
3.1 %), all possessing 4-carbon atoms chains. Certainly, compound 6i 
incorporates an extra methylene within the benzyl, extending the length 
of the compound, but as in the benzyl series (6g, 6h, 6i) the length of the 
carbon chain does not appear to have a relationship between activity 
and the structure of the molecules. However the relevant structural 
feature in terms of activity appears to be related with the presence of 
the nitro group attached to the phenyl group. 
aGI50, concentration of compound required to cause 50% cell 
growth inhibition after a continuous exposure for 48h. Results are 
presented as means ± SE of at least three independent experiments 
performed in duplicate. ND: not determined. Further analysis of the 
results obtained from the heterocylic imine compounds revealed that 
the 2c compound bearing a thiophene unit together with a 2 atom 
carbon chain presented better activity than its furan and pyrrole 
counterparts on MCF-7 (45.5 ± 12.1 % inhibition), and HCT-15 (46.2 
± 9.3 % inhibition) cell lines. BxPC3 cell line was more sensitive to the 
furan compound 2b (33.5 ± 7.8 % inhibition). Compound 2a bearing 
a pyrrole ring was the least active among the 2 carbon atoms chain 
imine compounds. The amino compounds in its hydrochloride salts 
(3f and 3g), obtained from the heterocyclic imines 2f and 2g, showed 
no activity on any of the analyzed tumor cell lines. For the MCF-7 cell 
the best inhibitor compound obtained was the compound 6f with a 
percentage of cell growth inhibition of 84.5% at 5 µM and a GI50 of 
2.44 µM, close to the one found for the reference drug, doxorubicin, 
with 99.5% and a GI50 of 0.024 µM. HCT-15 was more susceptible to 
the compound 9d with 64.9% of cell growth inhibition at 5 µM, and 
a GI50 of 3.6 µM, similar to doxorubicin which presented 73.6% and a 
GI50 of 1.07 µM. These two compounds can be proposed as leaders for 
modification by medical chemistry. 
Toxicity of the compounds to non-tumor cells: The toxicity of 
the synthesized compounds was evaluated on THP-1 differentiated 
macrophages and compounds 1a, 2c, 6f and 9d were further tested 
on mouse bone marrow-derived macrophages (BMMØ) by the MTT 
assay. No toxicity was observed for a 10 µM concentration from most 
of the compounds on THP1 differentiated macrophages after 72h 
incubation (data not shown). The exception occurred with compound 
6f, which presented 61.1 ± 3.0 % of cell viability, value below the 
minimum considered as non-toxic in the screening of new compounds 
(70 %). However, toxicity assays performed on BMMØ with 5 µM and 
50 µM compound concentrations revealed no toxicity of compound 6f 
for any of the concentrations tested (Table 3). Results are presented as 
means ± SE of two independent experiments performed in triplicate. 
This contradictory result may be related with the fact that THP1 
differentiated macrophages derived from an immortalized cell line, 
which although not tumorigenic is derived from the peripheral blood 
of a patient with acute monocytic leukemia in contrast with the primary 
non-tumor BMMØ. Also, no toxicity was observed on BMMØ for 
compounds 1a, 2c and 9d at a concentration of 5 µM. It is noteworthy 
to mention that at 50 µM concentration, compound 1a induced a 
decrease in cell viability to 46.2 ± 12.9 % and compound 2c to 67.3 ± 
Compound Inhibition of cell growth (%)
(5 µM) MCF-7 HCT-15 BxPC-3
1a 62.4 ± 4.4 37.0 ± 7.7 33.8 ± 2.6
1b 19.9 ± 3.3 18.6 ± 0.9 10.1 ± 3.7
2a 19.7 ± 3.6 9.3 ± 3.7 17.6 ± 3.2
2b 30.1 ± 5.5 28.2 ± 5.5 33.5 ± 7.8
2c 45.5 ± 12.1 46.2 ± 9.3 15.9 ± 8.8
2d 20.9 ± 2.4 12.4 ± 4.4 15.4 ± 1.4
2e 18.7 ± 2.4 17.2 ± 1.8 12.2 ± 6.7
2f 19.7 ± 8.8 15.8 ± 4.2 3.5 ± 6.2
2g 15.4 ± 3.7 18.1 ± 3.5 10.9 ± 3.0
2h 27.1 ± 3.0 25.2 ± 5.7 15.0 ± 5.1
2i 9.4 ± 0.6 16.7 ± 5.3 2.6 ± 3.2
3f NA NA NA
3g NA NA NA
4a 29.0 ± 1.4 11.8 ± 3.3 42.4 ± 1.6
4b NA 9.1 ± 4.4 NA
6d 14.0 ± 5.9 10.7 ± 1.7 3.9 ± 1.7
6e 28.3 ± 4.1 15.4 ± 1.5 9.5 ± 1.9
6f 84.5 ± 3.2 42.8 ± 3.0 28.5 ± 6.8
6g 9.1 ± 1.4 9.4 ± 6.4 NA
6h 6.9 ± 3.1 7.3 ± 2.8 NA
6i 10.8 ± 0.6 8.8 ± 6.6 NA
6l 8.6 ± 3.1 8.2 ± 2.6 NA
9d 46.5 ± 5.9 64.9 ± 7.7 32.9 ± 7.9
9e 31.5 ± 6.4 NA 23.7 ± 5.2
Doxorubicin 99.5 ± 0.3 73.6 ± 4.4 161.6 ± 5.7
Table 1: Effect of naphthalimide compounds 1a,b, 2a-I, 3f,g, 4a,b, 6d-l, 9d,e compared to doxorubicin on the growth of MCF-7, HCT-15, and BxPC-3 human tumor cell lines.
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16.6 %. These values suggest some toxicity of these two compounds 
only at a concentration tenfold higher than the concentration used in 
our assays (5 µM).
Conclusions
Several naphthalimides were synthetized in good yields and showed 
very good GI50 values towards MCF-7, HCT-15, and BxPC-3 cancer cell 
lines. By changing the alkyl chain length between the naphthalimido 
group and the functionality at the end of the chain, it was possible to 
find the best structural features from 1,8-naphthalimido derivatives 
to achieve enhanced anticancer activity, either generically speaking 
either against each type of cancer cell line. From these results new 
perspectives can be drawn to improve the activity of naphthalimides 
as anticancer agents.
Experimental
Chemistry
General: All starting materials were purchased from Sigma-
Aldrich, were of research-grade quality and were used without further 
purification. Compounds were purified by dry flash chromatography, 
using silica 60 <0.063 mm and water pump vacuum. TLC plates (silica 
gel 60 F254, Macherey-Nagel) were visualized either at UV lamp or with 
I2. 1H NMR and 13C NMR were carried out on a Varian Unity Plus 
300 (300 MHz) and Brucker Avance III 400 (400 MHz) spectrometers. 
Infrared spectra were recorded on a Bomem MB 104. Samples were 
run as nujol mulls and oils as thin films. MS spectra were recorded on 
a VG Autospec M. spectrometer. Microanalyses were performed in a 
LECO-CHNS-932 analyzer. Melting points (m.p.) were determined on 
a Gallenkamp block and are uncorrected. The synthesis of compounds 
1a-c were described before.9a The yields were improved by increasing 
the number of equivalents of diamine, and by diminishing the 
coupling reaction time. Alcohols 1d-f were prepared by analogy to 
the synthesis reported for N-(3-propanol)-1,8-naphthalimide (1e)9b. 
The ammonium chloride salts were obtained by dissolving the amines 
in dichloromethane and treatment with the solution with HCl gas, 
produced by heating a concentrated solution of HCl, and passing the 
gas through H2SO4.
Synthesis of naphthalimide precursors with a terminal amino 
group, compounds 1a-c9a 
General procedure: To a solution of 1,8-naphthalic anhydride 
(1.00-2.00 g, 5.05-10.09 mmol) in ethanol (150-200 mL) was added the 
amine (2-6 equiv.). The reaction mixture was refluxed for 20 min-1 h, 
cooled down to r.t., and the precipitated solid filtered off. The solution 
was concentrated in the rotary evaporator, washed with diethyl ether, 
to give yellow solids 1a-c (83-93 %). 
Synthesis of 2-(2-aminoethyl)-1H-benzo(de)isoquinoline-
1,3(2H)-dione (1a): 1,8-Naphthalic anhydride (1.00 g, 5.05 mmol); 
ethanol (150 mL); 1,2-diaminoethane (6 equiv.); 1 h; yellow solid 1a 
(91 %); m.p.: 124-127°C; δH (400 MHz, CDCl3) 2.95 (2H, t, J=6.6 Hz), 
4.11 (2H, t, J=6.6 Hz), 7.53 (2H, t, J=7.8 Hz), 7.98 (2H, dd, J=8.4, 0.8 
Hz), 8.34 (2H, dd, J=7.6, 0.8 Hz) ppm.
Synthesis of 2-(3-aminopropyl)-1H-benzo(de)isoquinoline-
1,3(2H)-dione (1b): 1,8-Naphthalic anhydride (2.00 g, 10.09 mmol); 
ethanol (200 mL); 1,3-diaminopropane (2 equiv.); 20 min; yellow solid 
1b (93 %); m.p.: 126-130°C; νmax (Nujol) 1655, 3346 cm-1; δH (400 MHz, 
CDCl3) 1.89 (2H, quint, J=6.8 Hz), 2.76 (2H, t, J=6.6 Hz), 4.27 (2H, t, 
J=7.0 Hz), 7.73 (2H, dd, J=8.0, 7.2 Hz), 8.19 (2H, dd, J=8.4, 1.2 Hz), 
8.57 (2H, dd, J=7.4, 1.0 Hz) ppm; δC (100 MHz, CDCl3) 32.1, 37.7, 39.4, 
122.5, 126.9, 128.1, 131.2, 131.5, 133.9, 164.2 ppm.
Synthesis of 2-(4-aminobutyl)-1H-benzo(de)isoquinoline-
1,3(2H)-dione (1c): 1,8-Naphthalic anhydride (2.00 g, 10.09 mmol); 
ethanol (200 mL); 1,4-diaminobutane (2 equiv.); 1 h; yellow solid 1c 
(83 %); m.p.: 105-109°C; δH (400 MHz, CDCl3) 1.47-1.55 (2H, m), 1.64-
1.74 (2H, m), 2.70 (2H, t, J=7.0 Hz), 4.09 (2H, t, J=7.4 Hz), 7.61 (2H, 
dd, J=8.2, 7.4 Hz), 8.06 (2H, dd, J=8.4, 1.2 Hz), 8.43 (2H, dd, J=7.2, 0.8 
Hz) ppm.
Synthesis of naftalimide precursors with a terminal hydroxyl 
group, compounds 1d-f
General procedure: To a solution of 1,8-naphthalic anhydride 
(1.00-2.03 g, 5.05-10.25 mmol), in DMF (12-24 mL) was added the 
amino-alcohol (10 equiv.) and DBU (1 equiv.). The reaction mixture 
was stirred in an oil bath at 75°C, for 4-7 h. Dichloromethane (100 mL) 
was added, the solution washed with water (5x60 mL) and the organic 
phase, dried over magnesium sulfate, filtered and concentrated in the 
rotary evaporator to give compounds 1d-f (88-96 %) as pale yellow 
solids.
Synthesis of 2-(2-hydroxy-ethyl)-1H-benzo(de)isoquinoline-
1,3(2H)-dione (1d): 1,8-Naphthalic anhydride (2.03 g, 10.13 mmol); 
DMF (24 mL); 2-aminoethanol (10 equiv.); DBU (1 equiv.); 7 h; yellow-
brown solid 1d (88 %); m.p.: 164-167°C; νmax (Nujol) 1650, 3482 cm-1; 
δH (400 MHz, CDCl3) 3.99 (2H, t, J=5.4 Hz), 4.47 (2H, t, J=5.2 Hz), 
7.76 (2H, dd, J=8.4, 7.2 Hz), 8.22 (2H, dd, J=8.4, 0.8 Hz), 8.60 (2H, dd, 
J=7.4, 1.0 Hz) ppm; δC (100 MHz, CDCl3) 42.8, 61.7, 122.4, 127.0, 128.2, 
131.5, 131.5, 134.2, 165.1 ppm. MS: m/z 242 (M+1)+.
Synthesis of 2-(3-hydroxypropyl)-1H-benzo(de)isoquinoline-
1,3(2H)-dione (1e) 9b: 1,8-Naphthalic anhydride (2.03 g, 10.25 mmol); 
DMF (24 mL); 3-aminopropanol (10 equiv.); DBU (1 equiv.); 7 h; pale 
yellow solid 1e (96 %); m.p.: 115-118°C; δH (400 MHz, CDCl3) 1.96-
2.04 (2H, m), 3.14 (1H, t, J=7.0 Hz), 3.60 (2H, q, J=6.0 Hz), 4.36 (2H, t, 
J=6.2 Hz), 7.77 (2H, dd, J=8.2, 7.4 Hz), 8.24 (2H, dd, J=8.2, 1.0 Hz), 8.62 
(2H, dd, J=7.2, 1.2 Hz) ppm. MS: m/z 256 (M+1)+.
Synthesis of 2-(4-hydroxybutyl)-1H-benzo(de)isoquinoline-
1,3(2H)-dione (1f): 1,8-Naphthalic anhydride (1.00 g, 5.05 mmol); 
DMF (12 mL); 4-aminobutanol (10 equiv.); DBU (1 equiv.); 4 h; pale 
yellow solid 1f (91 %); m.p.: 109-111°C; νmax (Nujol) 1655, 3510 cm-1; 
δH (400 MHz, CDCl3) 1.66-1.76 (2H, m), 1.80-1.90 (2H, m), 3.75 (2H, 
t, J=6.4 Hz), 4.23 (2H, dd, J=8.0, 6.8 Hz), 7.75 (2H, dd, J=8.2, 7.4 Hz), 
8.20 (2H, dd, J=8.4, 0.8 Hz), 8.59 (2H, dd, J=7.4, 1.0 Hz) ppm; δC (100 
Compound GI50 (µM)
a
MCF-7 HCT-15
1a 4.23 ± 0.50 ND
2c > 5 > 5
6f 2.44 ± 0.25 ND
9d > 5 3.60 ± 0.06
Doxorubicin 0.024 ± 0.007 1.07 ± 0.18
Table 2: Determination of the GI50 concentration of the most active naphthalimide 
compounds on different human tumor cell lines.
Compound % relative cell viability
5 µM 50 µM
1a 88.2 ± 4.5 46.2 ± 12.9
2c 108.9 ± 7.9 67.3 ± 16.6
6f 118.5 ± 11.5 111.6 ± 8.2
9d 85.8 ± 1.6 93.3 ± 10.2
Table 3: Toxicity of compounds 1a, 2c, 6f, and 9d on BMMØ.
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MHz, CDCl3) 24.5, 29.9, 39.9, 62.5, 122.6, 126.9, 128.1, 131.2, 131.5, 
133.9, 164.2 ppm. MS: m/z 270 (M+1)+.
Synthesis of imines 2a-i
General procedure: To a solution of 1,8-naphthalimide 1a-c (92-
413 mg, 0.38-1.63 mmol) in ethanol (5-12 mL) was added the aldehyde 
(1-1.2 eq.), and the mixture refluxed for 20 min-7 h. A solid precipitated 
out at rt or by cooling at - 20°C. The solid formed was filtrated, washed 
with ethanol, to give the respective imine (compounds 2a-i; 61.7-100 
%). 
Synthesis of (E)-2-(2-(((1H-pyrrol-2-yl)methylene)amino)ethyl 
-1H-benzo[de]isoquinoline-1,3(2H)-dione (2a): Compound 1a (247 
mg, 1.03 mmol); pyrrol-2-carboxaldehyde (1.2 equiv.); ethanol (10 
mL); 1 h; salmon solid (85.2 %); m.p.: 195-198°C; νmax (Nujol) 3180, 
1695, 1657, 1639 cm-1; δH (400 MHz, CDCl3) 3.89 (2H, t, J=6.6 Hz), 4.50 
(2H, t, J=6.8 Hz), 6.18 (1H, dd, J=3.2, 2.4 Hz), 6.40 (1H, dd, J=3.6, 1.6 
Hz), 6.88 (1H, dd, J=2.0, 1.2 Hz), 7.75 (2H, dd, J=8.4, 7.6 Hz), 8.06 (1H, 
d, J=0.4 Hz), 8.21 (2H, dd, J=8.4, 1.2 Hz) 8.60 (2H, dd, J=7.2, 1.2 Hz) 
ppm; δC (100 MHz, CDCl3) 40.9, 57.9, 109.6, 114.5, 122.0, 122.6, 126.9, 
128.2, 130.0, 131.3, 131.6, 133.9, 153.1, 164.2 ppm; HRMS (FAB): calcd 
for C19H15N3O2: 318.1237 (M+1); obtained: 318.1234.
Synthesis of (E)-2-(2-((furan-2-ylmethylene)amino)ethyl-1H-
benzo[de]isoquinoline-1,3(2H)-dione (2b): Compound 1a (142 mg, 
0.59 mmol); furfural (1 equiv.); ethanol (6 mL); 4 h 50 min; brown solid 
(62.8 %); m.p.: 149-151°C; νmax (Nujol) 1653, 1584 cm-1; δH (400 MHz, 
CDCl3) 3.94 (2H, t, J=8.2 Hz), 4.55 (2H, t, J=8.2 Hz), 6.47 (1H, dd, 
J=3.6, 2.0 Hz), 6.76 (1H, dd, J=3.6, 0.4 Hz), 7.52 (1H, d, J=1.6 Hz), 7.77 
(2H, dd, J=8.4, 7.2 Hz), 8.19 (1H, d, J=1.2 Hz), 8.23 (2H, dd, J=8.4, 
1.2 Hz), 8.63 (2H, dd, J=7.2, 1.2 Hz) ppm; δC (100 MHz, CDCl3) 40.8, 
58.6, 111.6, 114.3, 122.6, 126.9, 128.2, 131.3, 131.6, 133.9, 144.8, 151.3, 
151.5, 164.1 ppm. Anal. Cald for C19H14N2O3: C, 71.69, H, 4.43, N, 8.80. 
Found: C, 71.14, H, 4.36, N, 8.68.
Synthesis of (E)-2-(2-((thiophen-2-ylmethylene)amino)ethyl)-
1H-benzo[de]isoquinoline-1,3(2H)-dione (2c): Compound 1a (92 
mg, 0.38 mmol); thiophene-2-carboxaldehyde (1 equiv.); ethanol (5 
mL); 6 h; brown solid (72.6 %); m.p.: 176-178°C; νmax (Nujol) 1692, 
1656, 1634 cm-1; δH (400 MHz, CDCl3) 3.94 (2H, t, J=7.0 Hz), 4.53 
(2H, t, J=6.8 Hz), 7.04 (dd, J=5.2, 4.0 Hz, 1H), 7.27 (1H, dd, J=3.6, 
1.2 Hz), 7.38 (1H, dt, J=5.2, 1.2 Hz), 7.76 (2H, dd, J=8.4, 7.2 Hz), 8.22 
(2H, dd, J=8.0, 0.8 Hz), 8.45 (1H, d, J=1.2 Hz), 8.62 (2H, dd, J=7.6, 1.2 
Hz) ppm; δC (100 MHz, CDCl3) 40.7, 58.2, 122.7, 126.9, 127.2, 128.2, 
129.1, 130.5, 131.3, 131.6, 133.9, 142.4, 155.9, 164.1 ppm. Anal. Cald 
for C19H14N2O2S: C, 68.24, H, 4.22, N, 8.38, S, 9.59. Found: C, 68.13, H, 
4.20, N, 8.34, S, 9.36.
Synthesis of (E)-2-(2-(((1H-imidazol-2-yl)methylene)amino)
ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (2d): Compound 1a 
(99 mg, 0.41 mmol); imidazol-2-carboxaldehyde (1 equiv.); ethanol (5 
mL); 20 min; white solid (quant.); m.p.: 221-222°C; νmax (Nujol) 3148, 
1696, 1649 cm-1; δH (400 MHz, CDCl3) 4.01 (2H, t, J=6.4 Hz), 4.57 (2H, 
t, J=6.4 Hz), 7.09 (1H, br s), 7.13 (1H, br s), 7.76 (2H, dd, J=8.4, 7.6 
Hz), 8.19 (1H, t, J=1.2 Hz), 8.22 (2H, dd, J=8.4 , 0.8 Hz), 8.60 (2H, 
dd, J=7.2, 1.2 Hz) ppm; δC (100 MHz, CDCl3) 40.6, 58.3, 118.0, 122.5, 
126.9, 128.2, 131.4, 131.6, 134.1, 144.8, 153.0, 164.3 ppm. Anal. Calcd 
for C18H14N4O2: C, 67.91, H, 4.43, N, 17.60. Found; C, 67.28, H, 4.33, 
N, 17.60.
Synthesis of (E)-2-(3-(((1H-pyrrol-2-yl)methylene)amino)
propyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (2e): Compound 
1b (136 mg, 0.54 mmol); pyrrol-2-carboxaldehyde (1 equiv.); ethanol 
(12 mL); 50 min; salmon solid (90.3 %); m.p.: 170-172°C; νmax (Nujol) 
3351, 1693, 1656, 1642 cm-1; δH (400 MHz, CDCl3) 2.13 (2H, quint, 
J=6.8 Hz), 3.65 (2H, dt, J=6.8, 1.2 Hz), 4.28 (2H, t, J=7.2 Hz), 6.18 (1H, 
dd, J=3.6, 2.4 Hz), 4.44 (1H, dd, J=3.6, 1.2 Hz), 6.82 (1H, dd, J=1.2, 0.4 
Hz), 7.74 (2H, dd, J=8.4, 7.6 Hz), 8.06 (1H, d, J=0.4 Hz), 8.19 (2H, dd, 
J=8.4, 0.8 Hz), 8.58 (2H, dd, J=7.6, 1.2 Hz) ppm; δC (100 MHz, CDCl3) 
29.3, 38.7, 58.2, 109.5, 114.6, 122.0, 122.6, 126.9, 128.1, 129.8, 131.2, 
131.5, 133.9, 152.2, 164.2 ppm; HRMS (FAB): calcd for C20H17N3O2: 
332.1389 (M+1); found: 332.1394.
Synthesis of (E)-2-(3-((furan-2-ylmethylene)amino)propyl)-1H-
benzo[de]isoquinoline-1,3(2H)-dione (2f)
Compound 1b (174 mg, 0.68 mmol); furfural (1 equiv.); ethanol 
(5 mL); 3h 20 min; brown solid (76.5 %); m.p.: 98-100°C; νmax (Nujol) 
1690, 1651 cm-1; δH (400 MHz, CDCl3) 2.20 (2H, quint. J=6.8 Hz), 3.71 
(2H, dt, J=6.8, 1.2 Hz), 4.31 (2H, t, J=6.8 Hz), 6.40 (1H, dd, J=3.6, 2.0 
Hz), 6.65 (1H, d, J=3.6 Hz), 7.41 (1H, d, J=1.6 Hz), 7.73 (2H, dd, J=8.0, 
7.2 Hz), 8.12 (1H, d, J=1.2 Hz), 8.19 (2H, dd, J=8.0, 1.2 Hz), 8.57 (2H, 
dd, J=7.2, 1.2 Hz) ppm; δC (100 MHz, CDCl3) 29.3, 38.6, 59.5, 111.4, 
113.6, 122.6, 126.8, 128.1, 131.1, 131.5, 133.8, 144.5, 150.1, 151.5, 164.2 
ppm. HRMS: calcd for C20H17O3N2: 333.1234 (M+1); found: 333.1234. 
Synthesis of (E)-2-(2-((thiophen-2-ylmethylene)amino)propyl)-
1H-benzo[de]isoquinoline-1,3(2H)-dione (2g): Compound 1b (127 
mg, 0.50 mmol); thiophene-2-carboxaldehyde (1 equiv.); ethanol (11 
mL); 1:30 h, brown solid (74.1 %); m.p.: 132-134°C; νmax (Nujol) 1688, 
1652 cm-1; δH (400 MHz, DMSO-d6) 1.98 (2H, quint. J=6.8 Hz), 3.59 
(2H, t, J=6.8 Hz), 4.13 (2H, t, J=6.8 Hz), 7.05 (1H, dd, J=5.2, 3.6 Hz), 
7.34 (1H, dd, J=3.6, 1.2 Hz), 7.52 (1H, dt, J=2.4, 1.2 Hz), 7.82 (2H, dd, 
J=8.4, 7.2 Hz), 8.40 (2H, dd, J=8.4, 1.2 Hz), 8.42 (1H, d, J=1.2 Hz), 8.45 
(2H, dd, J=7.2, 1.2 Hz) ppm; δC (100 MHz, DMSO-d6) 28.7, 38.2, 58.1, 
122.1, 127.1, 127.4, 127.5, 129.1, 130.6, 130.9, 131.2, 134.2, 142.2, 154.7, 
163.5 ppm; HRMS (FAB): calcd for C20H16N2O2S: 349.1004 (M+1); 
found: 349.1005.
Synthesis of (E)-2-(4-(((1H-pyrrol-2-yl)methylene)amino)
butyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (2h): Compound 
1c (151 mg, 0.56 mmol); pyrrol-2-carboxaldehyde (1 equiv.); ethanol 
(10 mL); 7 h; salmon solid (61.7 %); m.p.: 124-126°C; νmax (Nujol) 3346, 
1689, 1654, 1641 cm-1; δH (400 MHz, CDCl3) 1.79-1.80 (4H, m), 3.59 
(2H, t, J=6.4 Hz), 4.23 (2H, t, J=7.2 Hz), 6.20 (1H, dd, J=3.6, 2.8 Hz), 
6.45 (1H, dd, J=3.6, 1.6 Hz), 6.87-6.88 (1H, m), 7.74 (2H, dd, J=8.0, 7.2 
Hz), 8.05 (1H, d, J=0.8 Hz), 8.19 (2H, dd, J=8.4, 0.8 Hz), 8.59 (2H, dd, 
J=7.2, 1.2 Hz) ppm; δC (100 MHz, CDCl3) 25.8, 28.5, 40.1, 60.2, 109.5, 
114.1, 121.8, 122.7, 126.9, 128.1, 130.1, 131.2, 131.5, 133.8, 151.8, 164.2 
ppm; HRMS (FAB): calcd for C21H19N3O2: 346.1554 (M+1); found: 
346.1550.
Synthesis of (E)-2-(4-((thiophen-2-ylmethylene)amino)butyl)-
1H-benzo[de]isoquinoline-1,3(2H)-dione (2i): Compound 1c (413 
mg, 1.63 mmol); thiopene-2-carboxaldehyde (1 equiv.); ethanol (10 
mL); 2h 30 min, beige solid (72.6 %); m.p.: 103-105°C; νmax (Nujol) 
1696, 1657, 1635 cm-1; δH (400 MHz, DMSO-d6) 1.63-1.66 (4H, m), 
3.53 (2H, t, J=6.4 Hz), 4.05 (2H, t, J=6.8 Hz), 7.10 (1H, dd, J=4.8, 3.6 
Hz), 7.40 (1H, dd, J=3.6, 1.2 Hz), 7.60 (1H, dt, J=3.6, 1.2 Hz), 7.82 (2H, 
dd, J=8.0, 7.2 Hz), 8.40 (2H, dd, J=8.4, 0.8 Hz), 8.43 (1H, s), 8.44 (2H, 
dd, J=7.2, 1.2 Hz) ppm; δC (100 MHz, DMSO-d6) 25.4, 28.0, 56.0, 59.1, 
122.0, 127.2, 127.3, 127.7, 129.2, 130.7, 131.0, 131.2, 134.2, 142.3, 154.5, 
163.4 ppm; HRMS (FAB): calcd for C21H18N2O2S: 363.1171 (M+1); 
found: 363.1162.
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Synthesis of amines 3f,g
General procedure: To a stirred solution of imine 2f/g (32-80 
mg, 0.09-0.24 mmol) in a 1:1 mixture of THF (5 mL): MeOH (5 mL) 
was added NaBH4 (2 equiv.), the reaction continued at r.t. for 4-12 h. 
The solvents were removed in the rotary evaporator, DCM (30 mL) 
was added, and the solution washed with water (3x30 mL), dried over 
MgSO4, and the solvent removed in the rotary evaporator to give amines 
3f,g (75.0-83.9%) as oils. The respective oil (80-100 mg) was diluted in 
DCM (15 mL), HCl bubbled through for 2-4 h. The hydrochloride salt 
precipitated out of solution (53.4-55.2%). 
Synthesis of 2-(3-((furan-2-ylmethyl)amino)propyl)-1H-
benzo[de]isoquinoline-1,3(2H)-dione (3f): Imine 2f (80 mg, 0.24 
mmol); 4 h; orange oil (75.0 %); νmax 3067, 1697, 1657 cm-1; δH (400 
MHz, CDCl3) 1.99 (2H, quint, J=6.8 Hz), 2.73 (2H, t, J=6.8 Hz), 3.83 
(2H, s), 4.28 (2H, t, J=6.8 Hz), 6.19 (1H, dd, J=3.2, 0.8 Hz), 6.27 (1H, 
dd, J=3.2, 2.0 Hz), 7.31 (1H, dd, J=2.0, 0.8 Hz), 7.76 (2H, dd, J=8.4, 7.6 
Hz), 8.22 (2H, dd, J=8.4, 0.8 Hz), 8.60 (2H, dd, J=7.2, 1.2 Hz) ppm; 
δC (100 MHz, CDCl3) 28.1, 38.2, 45.9, 46.1, 107.1, 110.1, 122.6, 126.9, 
128.2, 131.3, 131.6, 133.9, 141.8, 153.6, 164.3 ppm. MS: m/z 334 (M+1)+. 
Hydrochloride ammonium salt: amine 3f (80 mg, 0.24 mmol); 2 
h; beige solid (55.2 %); δH (400 MHz, D2O) 2.06 (2H, quint, J=6.8 Hz), 
3.09 (2H, t, J=7.6 Hz), 4.02 (2H, t, J=6.8 Hz) 4.33 (2H, s), 6.39 (1H, dd, 
J=3.2, 1.6 Hz), 6.60 (1H, d, J=3.6 Hz), 7.50 (1H, d, J=1.2 Hz), 7.62 (2H, 
t, J=7.6 Hz), 8.13 (2H, d, J=8.0 Hz), 8.16 (2H, d, J=7.2 Hz) ppm. 
Synthesis of 2-(3-((thiophen-2-ylmethyl)amino)propyl)-1H-
benzo[de]isoquinoline-1,3(2H)-dione (3g): Imine 2g (32 mg, 0.09 
mmol); 12 h; orange oil (83.9 %); νmax 3307, 1692, 1653 cm-1; δH (400 
MHz, CDCl3) 2.00 (2H, quint, J=6.8 Hz), 2.77 (2H, t, J=6.8 Hz), 4.03 
(2H, s), 4.29 (2H, t, J=6.8 Hz), 6.92 (1H, dd, J=4.8, 3.6 Hz), 6.94-6.95 
(1H, m), 7.17 (1H, dd, J=4.8, 1.2 Hz), 7.76 (2H, dd, J=8.4, 7.6 Hz), 
8.22 (2H, dd, J=8.4, 0.8 Hz), 8.61 (2H, dd, J=7.6, 1.2 Hz) ppm; δC (100 
MHz, CDCl3) 28.1, 38.2, 46.1, 48.1, 122.6, 124.3, 125.0, 126.6, 126.9, 
128.2, 131.3, 131.6, 133.9, 143.8, 164.3 ppm. HRSM (FAB): calcd for 
C20H19N2O2S: 351.1162 (M+1); found: 351.1165.
Hydrochloride ammonium salt: amine 3g (100 mg, 0.29 mmol); 4 
h; white solid (53.4 %); δH (400 MHz, D2O) 2.05-2.10 (2H, m), 3.10 (2H, 
t, J=7.2 Hz), 4.03 (2H, J=6.0 Hz), 4.50 (2H, s), 6.97 (1H, dd, J=5.2, 3.6 
Hz), 7.24 (1H, dt, J=3.6, 0.8 Hz), 7.42 (1H, dd, J=5.2, 1.2 Hz), 7.62 (2H, 
t, J=7.6 Hz), 8.13-8.17 (4H, m) ppm.
Synthesis of guanidine 4a-c
General procedure: To a solution of 1,8-naphthalimide 
1a-c (0.13-0.41 g, 0.53-1.63 mmol) in THF (10 mL) was added 
2-methylisothiouronium iodide10 (1.3 equiv.) at r.t. The suspension was 
refluxed for 3h – 6h 30 min. A solid precipitated out from the reaction 
mixture by cooling at rt. Guanidines 4a-c (74.1-89.2 %) were obtained 
as white solids.
Synthesis of 1-(2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-
yl)ethyl)guanidine hydroiodide (4a): Compound 1a (0.13 g, 0.53 
mmol); THF (10 mL); 3 h; white solid (77.4 %); m.p.: 204-207°C. νmax 
(Nujol) 3429, 3195, 3168, 1693, 1652 cm-1. δH (400 MHz, DMSO-d6) 
3.09 (½ x2H, t, J=6.0 Hz)a), 3.49 (½ x2H, t, J=5.6 Hz)a), 4.19 (½ x2H, t, 
J=6.0 Hz)b), 4.26 (½ x2H, t, J=6.0 Hz)b), 6.2-7.7 (5H, br s), 7.88 (2H, t, 
J=7.2 Hz), 8.47 (2H, d, J=6.8 Hz), 8.49 (2H, d, J=7.2 Hz) ppm. δC (100 
MHz, DMSO-d6) 38.1c), 38.4c), 38.6c), 38.8c), 122.1, 122.2, 127.2, 127.5, 
130.7, 131.3, 134.4, 156.8, 163.7, 164.0 ppm. HRSM (FAB): calcd for 
C15H14N4O2: 283.1186 (M+1); found: 283.1190.
a),b) Signals of methylene Hs at C-1 and C-2 in the two conformations 
of compound 4a (1:1 ratio), probably resulting from hydrogen bonding. 
c) Signals related to the C-1 and C-2 of the two conformers.
Synthesis of 1-(3-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-
yl)propyl)guanidine hydroiodide (4b): Compound 1b (0.41 g, 1.63 
mmol); THF (10 mL); 6 h; white solid (74.1 %); m.p.: 255-257°C; νmax 
(Nujol) 3184, 3127, 3059, 1696, 1657 cm-1; δH (400 MHz, DMSO-d6) 
1.67-1.73 (2H, m, 20%) a), 1.80-1.86 (2H, quint., J=6.8 Hz, 22%)a), 1.93 
(2H, quint, J=6.8 Hz, 58 %) a), 2.87 (2H, t, J=7.6 Hz, 60.8 %)b), 3.13 (2H, 
t, J=6.8 Hz, 19.6 %) b), 3.19 (2H, t, J=6.8 Hz, 19.6%)b), 4.07 (2H, t, J=6.8 
Hz), 5.59-7.60 (5H, br s), 7.81 (2H, t, J=7.6 Hz), 8.40 (4H, d, J=7.6 Hz) 
ppm; δC (100 MHz, DMSO-d6) 26.0c), 27.4 a), 27.9 a), 37.0c), 37.1 c), 38.2 
b), 38.8 b), 121.9, 127.2, 127.3, 130.6, 131.2, 134.3, 156.6, 163.6 ppm. MS: 
m/z 297 (M-I)+. 
a),b) Signals of methylene Hs at C-2 and C-3, are relative to the 
two conformations (1:3 ratio) of compound 4b, probably resulting 
from hydrogen bonding. c) Signals for C-1, C-2 and C-3 of the major 
conformer.
Synthesis of 1-(4-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-
yl)butyl)guanidine hydroiodide (4c): Compound 1c (0.15 g, 0.56 
mmol); THF (10 mL); 6h 30 min; white solid (89.2%); m.p.: 224-226°C; 
νmax (Nujol) 3419, 3309, 3258, 3161, 1691, 1655 cm-1; δH (400 MHz, 
DMSO-d6) 1.51-1.56 (2H, m), 1.65-1.69 (2H, m), 3.10-3.15 (2H, m), 
4.07 (2H, t, J=7.2 Hz), 5.59-7.50 (5H, br s), 7.87 (2H, dd, J=8.4, 7.2 Hz), 
8.46 (2H, dd, J=8.4, 1.2 Hz), 8.49 (2H, dd, J=7.2, 1.2 Hz) ppm; δC (100 
MHz, DMSO-d6) 24.8, 26.3, 39.2, 40.6, 121.9, 127.2, 127.3, 130.7, 131.3, 
134.3, 156.6, 163.5 ppm. HRMS calcd for C17H19O2N4 311.1503; found: 
311.1501.
Synthesis of amides 5a-l 
General procedure: To a solution of compound 1a-c (0.10-0.15 
g, 0.37-0.62 mmol) in a solvent (12-15 mL) was added the anhydride 
(1.1-2.0 equiv.). The reaction mixture refluxed for 1 h-2 h 30 min., 
concentrated in the rotary evaporator and the resulting oil cooled 
to -20°C overnight. White, pale yellow, or brownish solids 5a-l was 
formed, filtered, and eventually recrystallized from ethanol (54-87 %).
Synthesis of N-(2-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-
yl)ethyl)acetamide (5a)
Compound 1a (0.15 g, 0.62 mmol); ethanol (14 mL); acetic 
anhydride (1.1 equiv.); 1 h; white solid 5a (76 %); m.p.: 198-200°C; νmax 
(Nujol) 1652, 1676, 3359 cm-1; δH (400 MHz, CDCl3) 1.90 (3H, s), 3.66 
(2H, q, J=5.4 Hz), 4.39 (2H, t, J=5.4 Hz), 6.23 (1H, br s), 7.76 (2H, dd, 
J=8.0, 7.2 Hz), 8.22 (2H, dd, J=8.4, 1.2 Hz), 8.59 (2H, dd, J=7.2, 1.2 Hz) 
ppm; δC (100 MHz, CDCl3) 23.2, 39.4, 39.6, 122.3, 127.0, 128.2, 131.5, 
131.6, 134.3, 164.8, 170.4 ppm. HRMS (FAB): calcd for C16H14N2O3: 
283.1077 (M+1); found: 283.1076.
Synthesis of N-(3-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-
yl)propyl)acetamide (5b)
Compound 1b (0.15 g, 0.59 mmol); ethanol (14 mL); acetic 
anhydride (1.1 equiv.); 1 h; white solid 5b (81 %); m.p.: 170-173°C; νmax 
(Nujol) 1659, 1696, 3293 cm-1; δH (400 MHz, CDCl3) 1.96 (2H, quint, 
J=6.3 Hz), 2.05 (3H, s), 3.26 (2H, q, J=6.1 Hz), 4.27 (2H, t, J=6.4 Hz), 
6.49 (1H, br s), 7.77 (2H, dd, J=8.4, 7.4 Hz), 8.42 (2H, dd, J=8.2, 1.0 Hz), 
8.60 (2H, dd, J=7.4, 1.0 Hz) ppm; δC (100 MHz, CDCl3) 23.5, 27.9, 36.1, 
37.5, 122.3, 127.0, 128.1, 131.5, 131.6, 134.2, 164.5, 170.2 ppm. HRMS 
(FAB): calcd for C17H16N2O3: 297.1234 (M+1); found: 297.1233.
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Synthesis of N-(4-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-
yl)butyl)acetamide (5c): Compound 1c (0.15 g, 0.56 mmol); ethanol 
(14 mL); acetic anhydride (1.1 equiv.); 1h 30 min; white solid 5c (80 
%); m.p.: 199-201°C; νmax (Nujol) 1658, 1695, 3301 cm-1; δH (400 MHz, 
CDCl3) 1.63 (2H, quint, J=7.2 Hz), 1.79 (2H, quint, J=7.5 Hz), 1.98 (3H, 
s), 3.34 (2H, q, J=6.5 Hz), 4.18 (2H, t, J=7.4 Hz), 5.96 (1H, br s), 7.74 
(2H, t, J=7.8 Hz), 8.20 (2H, d, J=8.4 Hz), 8.57 (2H, d, J=7.2 Hz) ppm; δC 
(100 MHz, CDCl3) 23.3, 25.4, 26.7, 39.1, 39.7, 122.5, 126.9, 128.1, 131.2, 
131.5, 134.0, 164.2, 170.1 ppm. MS: m/z 333 (M+Na)+.
Synthesis of N-(2-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-
yl)ethyl)-2,2,2-trifluoroacetamide (5d) : Compound 1a (0.15 g, 0.62 
mmol); dry DCM (15 mL); trifluoroacetic anhydride (2 equiv.); 2 h 
30 min; recrystallization; white solid 5d (77 %); m.p.: 186-189°C; νmax 
(Nujol) 1662, 1703, 3107 cm-1; δH (400 MHz, CDCl3) 3.74-3.80 (2H, m), 
4.47-4.52 (2H, m), 7.48 (1H, br s), 7.78 (2H, dd, J=8.2, 7.4 Hz), 8.25 
(2H, dd, J=8.4, 0.8 Hz), 8.62 (2H, dd, J=7.4, 1.0 Hz) ppm; δC (100 MHz, 
CDCl3) 38.8, 40.4, 115.7 (3F, q, J=286 Hz), 122.0, 127.1, 128.2, 131.6, 
131.8, 134.6, 157.6 (q, J=37 Hz), 165.1 ppm. HRMS (FAB): calcd for 
C16H12O3N2F3: 337.0795 (M+1); found: 337.0797.
Synthesis of N-(3-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-
yl)propyl)-2,2,2-trifluoroacetamide (5e): Compound 1b (0.15 g, 0.59 
mmol); dry DCM (15 mL); trifluoroacetic anhydride (2 equiv.); 2 h 
30 min; recrystallization; beige solid 5e (63 %); m.p.: 149-152°C; νmax 
(Nujol) 1655, 1697, 3097 cm-1; δH (400 MHz, CDCl3) 2.04 (2H, quint, 
J=6.0 Hz), 3.37 (2H, q, J=6.2 Hz), 4.29 (2H, t, J=6.0 Hz), 7.77 (1H, s), 
7.80 (2H, d, J=7.6 Hz), 8.26 (2H, dd, J=8.0, 0.8 Hz), 8.63 (2H, dd, J=7.4, 
1.0 Hz) ppm; δC (100 MHz, CDCl3) 27.4, 36.3, 37.1, 116.0 (3F, q, J=286 
Hz), 126.9, 127.1, 128.2, 131.7, 133.9, 134.5, 157.9 (q, J=36 Hz) 164.9 
ppm. MS: m/z 373 (M+Na)+.
Synthesis of N-(4-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-
yl)butyl)-2,2,2-trifluoroacetamide (5f): Compound 1c (0.15 g, 0.56 
mmol); dry DCM (15 mL); trifluoroacetic anhydride (2 equiv.); 2 h 30 
min; recrystallization; pale brown solid 5f (86 %); m.p.: 153-156°C; νmax 
(Nujol) 1657, 1698, 3108 cm-1; δH (400 MHz, CDCl3) 1.74 (2H, quint, 
J=6.8 Hz), 1.85 (2H, quint, J=7.1 Hz), 3.50 (2H, q, J=6.4 Hz), 4.22 (2H, 
t, J=7.2 Hz), 7.07 (1H, br s), 7.77 (2H, dd, J=8.2, 7.4 Hz), 8.24 (2H, dd, 
J=8.2, 1.0 Hz), 8.60 (2H, dd, J=7.2, 0.8 Hz) ppm; δC (100 MHz, CDCl3) 
27.2, 25.8, 39.3, 39.4, 115.9 (3F, q, J=286 Hz), 122.3, 127.0, 128.1, 131.5, 
131.6, 134.3, 157.5 (q, J=37 Hz), 164.5 ppm. MS: m/z 287 (M+Na)+.
Synthesis of (E)-4-((2-(1,3-dioxo-1H-benzo(de)isoquinolin-
2(3H)-yl)ethyl)amino)-4-oxobut-2-enoic acid (5g): Compound 1a 
(0.15 g, 0.62 mmol); ethanol (14 mL); maleic anhydride (1.1 equiv.); 1 
h; light yellow solid 5g (85 %); m.p.: 212-215°C; νmax (Nujol) 1625, 1664, 
1695, 3284 cm-1; δH (400 MHz, DMSO) 3.52 (2H, q, J=6.0 Hz), 4.20 (2H, 
t, J=6.0 Hz), 6.18 (2H, d, J=12.4 Hz), 6.25 (2H, d, J=12.4 Hz), 7.85 (2H, 
dd, J=8.4, 7.2 Hz), 8.46 (4H, ddd, J=9.4, 7.8, 1.0 Hz), 9.22 (1H, t, J=5.8 
Hz), 14.74 (1H, s) ppm; δC (100 MHz, DMSO) 37.0, 38.8, 122.1, 127.2, 
127.5, 130.7, 134.3, 131.3, 131.5, 132.9, 163.7, 165.4, 165.7 ppm. HRMS 
(FAB): calcd for C18H14O5N2Na 361.0795 (M+Na); found: 361.0794.
Synthesis of (E)-4-((3-(1,3-dioxo-1H-benzo(de)isoquinolin-
2(3H)-yl)propyl)amino)-4-oxobut-2-enoic acid (5h): Compound 1b 
(0.15 g, 0.59 mmol); ethanol (14 mL); maleic anhydride (1.1 equiv.); 1 
h; light yellow solid 5h (69 %); m.p.: 165-169°C; νmax (Nujol) 1629, 1656, 
1703, 3250 cm-1; δH (400 MHz, CDCl3) 2.07 (2H, quint, J=6.1 Hz), 3.40 
(2H, q, J=6.0 Hz), 4.30 (2H, t, J=6.2 Hz), 6.41 (2H, s), 7.81 (2H, t, J=7.8 
Hz), 7.95 (1H, br s), 8.28 (2H, dd, J=8.0, 0.8 Hz), 8.63 (2H, dd, J=7.4, 
1.0 Hz) ppm; δC (100 MHz, CDCl3) 27.2, 36.9, 37.3, 122.0, 127.2, 128.2, 
131.1, 131.6, 131.8, 134.7, 136.7, 165.0, 165.0, 166.0 ppm. HRMS (FAB): 
calcd for C19H16N2O5: 351.0975 (M+1); found: 351.0970.
Synthesis of (E)-4-((4-(1,3-dioxo-1H-benzo(de)isoquinolin-
2(3H)-yl)butyl)amino)-4-oxobut-2-enoic acid (5i)
Compound 1c (0.10 g, 0.37 mmol); ethanol (12 mL); maleic 
anhydride (1.1 equiv.); 1 h; white solid 5i (54 %); m.p.: 156-160°C; νmax 
(Nujol) 1629, 1657, 1692, 3355 cm-1; δH (400 MHz, CDCl3) 1.73 (2H, 
quint, J=6.8 Hz), 1.85 (2H, quint, J=7.2 Hz), 3.50 (2H, q, J=6.3 Hz), 4.20 
(2H, t, J=7.2 Hz), 6.32 (1H, d, J=12.8 Hz), 6.47 (1H, d, J=12.8 Hz), 7.75 
(2H, dd, J=8.2, 7.4 Hz), 8.17 (1H, br s), 8.22 (2H, dd, J=8.4, 1.2 Hz), 8.58 
(2H, dd, J=7.4, 1.0 Hz) ppm; δC (100 MHz, CDCl3) 25.2, 25.4, 39.4, 39.9, 
122.3, 127.0, 128.1, 131.5, 131.5, 131.6, 134.3, 136.1, 164.4, 165.6, 166.2 
ppm. MS: m/z 389 (M+Na)+.
Synthesis of 4-((2-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-
yl)ethyl)amino)-4-oxobutanoic acid (5j): Compound 1a (0.15 g, 0.62 
mmol); ethanol (14 mL); succinic anhydride (1.1 equiv.); 1 h 30 min; 
white solid 5j (87%); m.p.: 195-199°C; νmax (Nujol) 1640, 1657, 1696, 
3311 cm-1; δH (400 MHz, DMSO) 2.19 (2H, t, J=6.8 Hz), 2.33 (2H, t, 
J=6.8 Hz), 3.36 (2H, t, J=6.0 Hz), 4.11 (2H, t, J=6.0 Hz), 7.85 (2H, dd, 
J=8.0, 7.2 Hz), 7.97 (1H, t, J=6.0 Hz), 8.43 (2H, dd, J=8.4, 1.2 Hz), 8.46 
(2H, dd, J=7.6, 1.2 Hz), 12.00 (1H, s) ppm; δC (100 MHz, DMSO) 29.1, 
30.2, 36.5, 39.4, 122.3, 127.2, 127.5, 130.6, 131.3, 134.2, 163.6, 171.2, 
173.8 ppm. HRMS (FAB): calcd for C18H16N2O5: 339.0986 (M+1); 
found: 339.0979.
Synthesis of 4-((3-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-
yl)propyl)amino)-4-oxobutanoic acid (5k): Compound 1b (0.15 
g, 0.59 mmol); ethanol (14 mL); succinic anhydride (1.1 equiv.); 1 h; 
beige solid 5k (66 %); m.p.: 165-168°C; νmax (Nujol) 1644, 1658, 1695, 
3293 cm-1; δH (400 MHz, DMSO) 1.70 -1.80 (2H, m), 2.29 (2H, t, J=6.8 
Hz), 2.39 (2H, t, J=7.2 Hz), 3.11 (2H, q, J=6.6 Hz), 4.11 (2H, t, J=7.2 
Hz), 7.83 (2H, dd, J=8.0, 7.6 Hz), 7.89 (1H, t, J=5.6 Hz), 8.41 (2H, dd, 
J=8.4, 0.8 Hz), 8.45 (2H, dd, J=7.2, 0.8 Hz) ppm; δC (100 MHz, DMSO) 
28.0, 29.5, 30.3, 36.6, 37.8, 122.0, 127.2, 127.3, 130.7, 131.3, 134.3, 
163.4, 171.0, 174.0 ppm. HRMS (FAB): Calcd for C19H18N2O5: 353.1143 
(M+1); found: 353.1139.
Synthesis of 4-((4-(1,3-dioxo-1H-benzo (de)isoquinolin-2(3H)-
yl)butyl)amino)-4-oxobutanoic acid (5l): Compound 1c (0.15 g, 0.56 
mmol); ethanol (14 mL); succinic anhydride (1.1 equiv.); 1 h; white 
solid 5l (66 %); m.p.: 169-171°C; νmax (Nujol) 1648, 1666, 1699, 3188, 
3356 cm-1; δH (400 MHz, DMSO) 1.43 (2H, quint, J=7.4 Hz), 1.62 (2H, 
quint, J=7.5 Hz), 2.27 (2H, t, J=6.8 Hz), 2.38 (2H, t, J=7.2 Hz), 3.05 
(2H, q, J=6.5 Hz), 4.02 (2H, t, J=7.2 Hz), 7.82 (1H, t, J=7.4 Hz), 7.84 
(2H, t, J=7.8 Hz), 8.42 (2H, dd, J=7.8, 0.8 Hz), 8.46 (2H, dd, J=7.2, 0.8 
Hz) ppm; δC (100 MHz, DMSO) 25.2, 26.8, 29.3, 30.1, 38.4, 39.4, 122.0, 
127.2, 127.3, 130.7, 131.3, 134.3, 163.4, 170.8, 173.9 ppm. HRMS (FAB): 
calcd for C20H20N2O5: 367.1299 (M+1); found: 367.1295.
Synthesis of ureas 6a-l 
General procedure: To a solution of compounds 1a-c (0.15-0.26 
g, 0.56-0.83 mmol) in dry toluene (8-16 mL). Kept stirring under 
nitrogen atmosphere in an ice/water bath, was added dropwise the 
isocyanate (1.0-2.5 equiv.). After addition is complete the reaction 
mixture was stirred for 1 h at rt, and then refluxed at 130°C in an oil 
bath for 4-6 h. The reaction mixture was concentrated in the rotary 
evaporator, refrigerated at -20°C for 20 h to give white, yellow solids 
as products, which are eventually purified by column chromatography 
(silica; solvent), 6a-l (55-98 %).
Synthesis of 1-(2-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-
yl)ethyl)urea (6a): Compound 1a (0.20 g, 0.83 mmol); dry toluene (15 
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mL); trimethylsilyl isocyanate (2.5 equiv.); 4 h; column (DCM:ethanol, 
85:15); fluffy white solid 6a (55 %); m.p.: 217-219°C; νmax (Nujol) 1653, 
1693, 3370, 3493 cm-1; δH (400 MHz, DMSO) 3.30 (2H, q, J=5.5 Hz), 
4.10 (2H, t, J=6.2 Hz), 5.34 (2H, br s), 6.04 (1H, t, J=6.2 Hz), 7.85 (2H, 
dd, J=8.2, 7.4 Hz), 8.42 (2H, dd, J=8.4, 0.8 Hz), 8.46 (2H, dd, J=7.4, 1.0 
Hz) ppm; δC (100 MHz, DMSO) 37.2, 40.1, 122.2, 127.1, 127.5, 130.6, 
131.3, 134.1, 158.6, 163.5 ppm. MS: m/z 306 (M+Na)+.
Synthesis of 1-(3-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-
yl)propyl)urea (6b): Compound 1b (0.20 g, 0.79 mmol); dry toluene 
(15 mL); trimethylsilyl isocyanate (2.5 equiv.); 5 h; white solid 6b (97 
%); m.p.: 205-208°C; νmax (Nujol) 1659, 1702, 3328, 3449 cm-1; δH (400 
MHz, DMSO) 1.72 (2H, quint, J=7.0 Hz), 3.03 (2H, q, J=6.5 Hz), 4.04 
(2H, t, J=7.2 Hz), 5.38 (2H, br s, NH2, 25 %)a), 5.46 (2H, br s, NH2, 75 
%) a), 5.90 (1H, t, J=5.6 Hz, NH, 25 %) a), 5.97 (1H, t, J=5.8 Hz, NH, 75 
%) a), 7.84 (2H, dd, J=7.2, 1.2 Hz), 8.42 (2H, dd, J=8.2, 1.0 Hz), 8.46 (2H, 
dd, J=7.2, 1.2 Hz) ppm; δC (100 MHz, DMSO) 28.9, 37.1, 37.7, 122.0, 
127.2, 127.3, 130.7, 131.3, 134.3, 158.7, 163.5 ppm. HRMS (FAB) calcd 
for C16H16N3O3 298.1186 (M+1); found: 298.1186.
a) Duplication of peaks probably due to different hydrogen bonding 
structures.
Synthesis of 1-(4-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-
yl)butyl)urea (6c): Compound 1c (0.20 g, 0.75 mmol); dry toluene 
(15 mL); trimethylsilyl isocyanate (2.5 equiv.); 5 h; white solid 6c (71 
%); m.p.: 198-201°C; νmax (Nujol) 1660, 1699, 3301, 3460 cm-1; δH (400 
MHz, DMSO) 1.41 (2H, quint, J=7.4 Hz), 1.61 (2H, quint, J=7.5 Hz), 
2.97 (2H, q, J=6.5 Hz), 4.03 (2H, t, J=7.2 Hz), 5.34 (2H, br s), 5.91 (1H, 
t, J=5.6 Hz), 7.84 (2H, dd, J=8.0, 7.2 Hz), 8.42 (2H, dd, J=7.2, 0.8 Hz), 
8.46 (2H, dd, J=8.4, 0.6 Hz) ppm; δC (100 MHz, DMSO) 25.2, 27.5, 27.7, 
39.0, 122.0, 127.2, 127.3, 130.7, 131.3, 134.3, 158.7, 163.4 ppm. HRMS 
(FAB) calcd for C17 H18 O3 N3: 312.1343 (M+1); found 312.1342.
Synthesis of 1-(2-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-yl)
ethyl)-3(4-nitrophenyl)urea (6d): Compound 1a (0.20 g, 0.83 mmol); 
dry toluene (8 ml); 4-nitrophenyl isocyanate (1 equiv.) dissolved in dry 
toluene (8 ml); 4 h; light yellow solid 6d (98 %); m.p.: 242-244°C; νmax 
(Nujol) 1329, 1555, 1659, 1700, 3391 cm-1; δH (400 MHz, DMSO) 3.47 
(2H, q, J=5.8 Hz), 4.21 (2H, t, J=5.8 Hz), 6.55 (1H, t, J=6.0 Hz), 7.48 
(2H, d, J=9.2 Hz), 7.82 (2H, dd, J=8.2, 7.4 Hz), 8.02 (2H, d, J=9.2 Hz), 
8.41 (2H, dd, J=8.4, 1.2 Hz), 8.44 (2H, dd, J=8.4, 1.2 Hz), 9.26 (1H, br s) 
ppm; δC (100 MHz, DMSO) 37.6, 39.7, 116.8, 122.2, 125.0, 127.1, 127.5, 
130.7, 131.3, 134.2, 140.3, 147.2, 154.7, 163.7 ppm. Anal. Calcd for 
C21H16N4O5: C 62.37, H 3.99, N 13.86. Found: C 62.22, H 3.84, N 13.73.
Synthesis of 1-(3-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-
yl)propyl)-3(4-nitrophenyl)urea (6e): Compound 1b (0.20 g, 0.79 
mmol); dry toluene (8 ml); 4-nitrophenyl isocyanate (1 equiv.) 
dissolved in dry toluene (8 mL); 5 h; yellow solid 6e (92 %); m.p.: 221-
224°C; νmax (Nujol) 1376, 1564, 1693, 1701, 3310 cm-1; δH (400 MHz, 
DMSO) 1.82 (2H, quint, J=6.7 Hz), 3.18 (2H, q, J=6.4 Hz), 4.09 (2H, 
t, J=6.8 Hz), 6.53 (1H, t, J=5.8 Hz), 7.58 (2H, d, J=9.2 Hz), 7.83 (2H, t, 
J=7.6 Hz), 8.09 (2H, d, J=9.2 Hz), 8.41 (2H, d, J=8.0 Hz), 8.46 (2H, d, 
J=7.2 Hz), 9.44 (1H, br s) ppm; δC (100 MHz, DMSO) 28.3, 37.0, 37.5, 
116.7, 122.0, 125.1, 127.2, 127.4, 130.7, 131.3, 134.3, 140.3, 147.3, 154.4, 
163.6 ppm. HRMS (FAB) calcd for C22H19O5N4: 419.1350 (M+1); found 
419.1350.
Synthesis of 1-(4-(1,3-dioxo-1H-benzo(de)isoquinolin-2(3H)-yl)
butyl)-3(4-nitrophenyl)urea (6f): Compound 1c (0.15 g, 0.56 mmol); 
dry toluene (8 ml); 4-nitrophenyl isocyanate (1 equiv.) dissolved in dry 
toluene (8 ml); 5 h; column (DCM:etanol, 95:5); yellow solid 6f (80%); 
m.p.: 232-235°C; νmax (Nujol) 1376, 1558, 1638, 1696, 3330 cm-1; δH (400 
MHz, DMSO) 1.52 (2H, quint, J=7.2 Hz), 1.67 (2H, quint, J=7.4 Hz), 
3.14 (2H, q, J=6.4 Hz), 4.06 (2H, t, J=7.2 Hz), 6.44 (1H, t, J=5.4 Hz), 
7.56 (2H, d, J=9.2 Hz), 7.84 (2H, dd, J=7.8, 7.4 Hz), 8.08 (2H, d, J=9.2 
Hz), 8.42 (2H, dd, J=8.4, 0.8 Hz), 8.46 (2H, dd, J=7.4, 1.0 Hz), 9.20 (1H, 
br s) ppm; δC (100 MHz, DMSO) 25.1, 27.2, 39.0, 39.4, 116.7, 122.0, 
125.1, 127.2, 127.3, 130.7, 131.3, 134.3, 140.3, 147.2, 154.4, 163.4 ppm. 
HRMS (FAB) calcd for C23H21O5N4: 433.1506 (M+1); found 433.1506.
Synthesis of 1-benzyl-3-(2-(1,3-dioxo-1H-benzo(de)isoquinolin-
2(3H)-yl)ethyl)urea (6g): Compound 1a (0.20 g, 0.83 mmol); dry 
toluene (15 mL); benzyl isocyanate (1 equiv.); 4 h; white solid 6g (96 
%); m.p.: 223-225°C; νmax (Nujol) 1661, 1696, 3324 cm-1; δH (400 MHz, 
DMSO) 3.39 (2H, q, J=6.1 Hz), 4.08 (2H, d, J=6.0 Hz), 4.14 (2H, t, J=6.0 
Hz), 6.06 (1H, t, J=6.0 Hz), 6.26 (1H, t, J=6.0 Hz), 7.10-7.23 (5H, m), 
7.85 (2H, dd, J=8.0, 7.2 Hz), 8.42 (2H, dd, J=8.2, 1.0 Hz), 8.47 (2H, dd, 
J=7.2, 1.2 Hz) ppm; δC (100 MHz, DMSO) 37.4, 40.2, 42.8, 122.2, 126.4, 
126.8, 128.0, 127.2, 127.5, 130.6, 131.3, 134.1, 140.9, 158.1, 163.6 ppm. 
Anal. Calcd for C22H19N3O3: C 70.76, H 5.13, N 11.25. Found: C 70.72, 
H 4.92, N 11.32.
Synthesis of 1-benzyl-3-(3-(1,3-dioxo-1H-benzo(de)isoquinolin-
2(3H)-yl)propyl)urea (6h)
Compound 1b (0.20 g, 0.79 mmol); dry toluene (16 mL); benzyl 
isocyanate (1 equiv.); 5 h; beige solid 6h (86 %); m.p.: 203-205°C; νmax 
(Nujol) 1654, 1695, 3311 cm-1; δH (400 MHz, DMSO) 1.75 (2H, quint, 
J=7.0 Hz), 3.09 (2H, q, J=6.5 Hz), 4.04 (2H, t, J=7.2 Hz), 4.19 (2H, d, 
J=6.0 Hz), 5.95 (1H, t, J=5.8 Hz, NH, 21.4 %) a), 6.01 (1H, t, J=5.8 Hz, 
NH, 78.6 %) a), 6.34 (1H, t, J=6.0 Hz, NH, 21.4 %) a), 6.44 (1H, t, J=6.0 
Hz, NH, 78.6 %) a), 7.16-7.32 (5H, m), 7.84 (2H, dd, J=7.4, 0.8 Hz), 8.42 
(2H, dd, J=8.4, 0.8 Hz), 8.46 (2H, dd, J=7.2, 1.2 Hz) ppm; δC (100 MHz, 
DMSO) 28.9, 37.3, 37.7, 42.9, 122.0, 126.5, 126.9, 128.2, 127.2, 127.3, 
130.7, 131.3, 134.3, 140.9, 158.0, 163.5 ppm. HRMS (FAB) calcd for C23 
H22 O3 N3: 388.1654 (M+1); found 388.1656.
a) Duplication of peaks probably due to different hydrogen bonding 
structures.
Synthesis of 1-benzyl-3-(4-(1,3-dioxo-1H-benzo(de)isoquinolin-
2(3H)-yl)butyl)urea (6i): Compound 1c (0.20 g, 0.75 mmol); dry 
toluene (15 mL); benzyl isocyanate (1 equiv.); 5 h; white solid 6i (91 
%); m.p.: 216-218°C; νmax (Nujol) 1667, 1702, 3310 cm-1; δH (400 MHz, 
DMSO) 1.43 (2H, quint, J=7.3 Hz), 1.62 (2H, quint, J=7.5 Hz), 3.04 
(2H, q, J=6.5 Hz), 4.04 (2H, t, J=7.4 Hz), 4.16 (2H, d, J=6.4 Hz), 5.93 
(1H, t, J=5.6 Hz), 6.26 (1H, t, J=5.8 Hz), 7.12-7.31 (5H, m), 7.84 (2H, 
dd, J=7.4, 0.8 Hz), 8.43 (2H, dd, J=8.4, 0.8 Hz), 8.47 (2H, dd, J=7.2, 1.2 
Hz) ppm; δC (100 MHz, DMSO) 25.2, 27.8, 39.2, 39.5, 42.8, 122.0, 126.4, 
126.5, 126.9, 127.0, 128.1, 128.2, 127.2, 127.3, 130.7, 131.3, 134.3, 141.0, 
158.1, 163.4 ppm. HRMS (FAB) calcd for C24 H23 O3 Na N3: 424.1632 
(M+Na+); found 424.1621.
Synthesis of 1-butyl-3-(2-(1,3-dioxo-1H-benzo(de)isoquinolin-
2(3H)-yl)ethyl)urea (6j): Compound 1a (0.20 g, 0.83 mmol); dry 
toluene (16 mL); butyl isocyanate (1 equiv.); 5 h; white solid 6j (88 
%); m.p.: 201-203°C; νmax (Nujol) 1660, 1696, 3323 cm-1; δH (400 MHz, 
DMSO) 0.74 (3H, t, J=7.0 Hz), 1.08-1.16 (4H, m), 2.81 (2H, q, J=6.4 
Hz), 3.33 (2H, q, J=6.0 Hz), 4.09 (2H, t, J=6.0 Hz), 5.72 (1H, t, J=5.8 
Hz), 5.87 (1H, t, J=6.0 Hz), 7.83 (2H, dd, J=8.2, 7.4 Hz), 8.40 (2H, dd, 
J=8.4, 1.2 Hz), 8.44 (2H, dd, J=7.4, 1.0 Hz) ppm; δC (100 MHz, DMSO) 
13.6, 19.4, 32.0, 37.3, 38.9, 40.2, 122.2, 127.1, 127.4, 130.5, 131.3, 134.1, 
158.1, 163.5 ppm. Anal. Calcd for C19H21N3O3: C 67.24, H 6.24, N 12.38; 
found: C 67.28, H 6.24, N 12.52.
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Synthesis of 1-butyl-3-(3-(1,3-dioxo-1H-benzo(de)isoquinolin-
2(3H)-yl)propyl)urea (6k): Compound 1b (0.20 g, 0.79 mmol); dry 
toluene (15 mL); butyl isocyanate (1.1 equiv.); 6 h; white solid 6k (84 
%); m.p.: 199-202°C; νmax (Nujol) 1665, 1699, 3319 cm-1; δH (400 MHz, 
DMSO) 0.84 (3H, t, J=7.2 Hz), 1.20-1.33 (4H, m), 1.71 (2H, quint, J=7.0 
Hz), 2.94 (2H, q, J=6.4 Hz), 3.04 (2H, q, J=6.5 Hz), 4.03 (2H, t, J=7.2 
Hz), 5.82 (1H, t, J=5.8 Hz), 5.89 (1H, t, J=5.6 Hz), 7.84 (2H, dd, J=8.2, 
0.8 Hz), 8.42 (2H, dd, J=8.4, 0.8 Hz), 8.45 (2H, dd, J=7.2, 1.2 Hz) ppm; 
δC (100 MHz, DMSO) 13.7, 19.6, 28.9, 32.2, 37.2, 37.8, 39.0, 122.1, 
127.2, 127.4, 130.7, 131.3, 134.3, 158.1, 163.5 ppm. HRMS (FAB) calcd 
for C20H24O3N3: 354.1812 (M+1); found 354.1812.
Synthesis of 1-butyl-3-(4-(1,3-dioxo-1H-benzo(de)isoquinolin-
2(3H)-yl)butyl)urea (6l)
Compound 1c (0.20 g, 0.75 mmol); dry toluene (16 mL); butyl 
isocyanate (1 equiv.); 5 h; white solid 6l (92%); m.p.: 204-207°C; νmax 
(Nujol) 1666, 1700, 3323 cm-1; δH (400 MHz, DMSO) 0.81 (3H, t, J=7.2 
Hz), 1.15-1.32 (4H, m), 1.40 (2H, quint, J=7.4 Hz), 1.60 (2H, quint, 
J=7.5 Hz), 2.92 (2H, q, J=6.4 Hz), 2.99 (2H, q, J=6.5 Hz), 4.03 (2H, t, 
J=7.2 Hz), 5.68-5.77 (2H, m), 7.85 (2H, t, J=7.8 Hz), 8.43 (2H, d, J=8.0 
Hz), 8.47 (2H, d, J=7.2 Hz) ppm; δC (100 MHz, DMSO) 13.7, 19.5, 25.2, 
27.8, 32.1, 38.9, 39.0, 39.1, 122.0, 127.2, 127.3, 130.7, 131.3, 134.3, 158.1, 
163.4 ppm. HRMS (FAB) calcd for C21 H26 O3 N3: 368.1969 (M+1); 
found 368.1969.
Synthesis of compounds 9d-f 
Conversion of alcohols 1d-f into bromides 7d-f
General procedure: To a solution of alcohols 1d-f (0.40-0.50 g, 1.49-
2.07 mmol) in DCM (8 mL) kept stirring in an ice/water bath was added 
carbon tetrabromide (1.6 equiv.) and triphenylphosphine (1.6 equiv.). 
Stirring was prolonged at rt for 12 to 24 h, then concentrated in the 
rotary evaporator, and the residue purified by column chromatography 
(silica, DCM:ethanol, 95:5). Products 7d-f were obtained as white or 
pale yellow solids (89-99 %).
Synthesis of 2-(2-bromoethyl)-1H-benzo(d,e)-isoquinoline-
1,3(2H)-dione (7d): Compound 1d (0.50 g, 2.07 mmol);12 h; pale 
yellow solid 7d (97 %); m.p.: 218-220°C; νmax (Nujol) 1658 cm-1; δH (400 
MHz, CDCl3) 3.69 (2H, t, J=7.2 Hz), 4.63 (2H, t, J=7.2 Hz), 7.79 (2H, 
t, J=7.8 Hz), 8.25 (2H, dd, J=8.0, 0.8 Hz), 8.64 (2H, dd, J=7.2, 0.8 Hz) 
ppm; δC (100 MHz, CDCl3) 27.8, 41.2, 122.3, 127.0, 128.2, 131.5, 131.6, 
134.3, 164.0 ppm. MS: m/z 326 (M+Na).
Synthesis of 2-(3-bromopropyl)-1H-benzo(de)-isoquinoline-
1,3(2H)-dione (7e): Compound 1e (0.50 g, 1.96 mmol); 24 h; white 
solid 7e (89 %); m.p.: 134-137°C; νmax (Nujol) 1661 cm-1; δH (400 MHz, 
CDCl3) 2.34 (2H, quint, J=6.9 Hz), 3.51 (2H, t, J=6.8 Hz), 4.33 (2H, t, 
J=7.2 Hz), 7.76 (2H, dd, J=8.2, 7.4 Hz), 8.22 (2H, dd, J=8.2, 1.0 Hz), 
8.60 (2H, dd, J=7.2, 1.2 Hz) ppm; δC (100 MHz, CDCl3) 30.5, 31.4, 
39.3, 122.5, 127.0, 128.1, 131.3, 131.6, 134.1, 164.2 ppm. MS: m/z 340 
(M+Na)+.
Synthesis of 2-(4-bromobutyl)-1H-benzo(de)-isoquinoline-
1,3(2H)-dione (7f): Compound 1f (0.40 g, 1.49 mmol); 20 h; white 
solid 7f (99 %); m.p.: 115-117°C; νmax (Nujol) 1665 cm-1; δH (400 MHz, 
CDCl3) 1.86-1.95 (2H, m), 1.96-2.03 (2H, m), 3.48 (2H, t, J=6.6 Hz), 
4.22 (2H, t, J=7.0 Hz), 7.75 (2H, dd, J=8.2, 7.4 Hz), 8.20 (2H, dd, J=8.4, 
1.2 Hz), 8.58 (2H, dd, J=7.2, 1.2 Hz) ppm; δC (100 MHz, CDCl3) 26.9, 
30.2, 33.1, 39.3, 122.5, 126.9, 128.1, 131.2, 131.5, 133.9, 164.1 ppm. 
Anal. Calcd for C16H14BrNO2: C 57.85, H 4.25, N 4.22. Found: C 57.62, 
H 4.28, N 4.01.
Conversion of bromides 7d-f into azides 8d-f
General procedure To a solution of compound 7d-7f (0.19-0.20 g, 
0.58-0.66 mmol) in dry DMF (3 mL) kept stirring under nitrogen was 
added sodium azide (3 equiv.). The suspension was stirred at rt for 3 
days. Dichloromethane (15 mL) was added and the mixture washed 
with water (6x10 mL). The combined organic layers were dried over 
magnesium sulfate, filtered and the solvent evaporated in the rotary 
evaporator to give products as white or yellow solids 8d-f (81-93 %).
Synthesis of 2-(2-azidoethyl)-1H-benzo(de)-isoquinoline-
1,3(2H)-dione (8d): Compound 7d (0.20 g, 0.66 mmol); yellow solid 
8d (88%); m.p.: 149-152°C; νmax (Nujol) 1657, 2102 cm-1; δH (400 MHz, 
CDCl3) 3.68 (2H, t, J=3.2 Hz), 4.46 (2H, t, J=3.2 Hz), 7.77 (2H, dd, 
J=7.8, 1.2 Hz), 8.23 (2H, dd, J=8.2, 1.0 Hz), 8.62 (2H, dd, J=7.2, 1.2 Hz) 
ppm; δC (100 MHz, CDCl3) 38.8, 48.9, 122.3, 127.0, 128.2, 131.5, 131.6, 
134.2, 164.2 ppm. MS: m/z 289 (M+Na)+.
Synthesis of 2-(3-azidopropyl)-1H-benzo(de)-isoquinoline-
1,3(2H)-dione (8e): Compound 7e (0.20 g, 0.63 mmol); white solid 
8e (81 %); m.p.: 89-92°C; νmax (Nujol) 1651, 2102 cm-1; δH (400 MHz, 
CDCl3) 2.06 (2H, quint, J=7.0 Hz), 3.45 (2H, t, J=6.8 Hz), 4.30 (2H, t, 
J=7.0 Hz), 7.76 (2H, dd, J=8.2, 7.4 Hz), 8.23 (2H, dd, J=8.4, 1.2 Hz), 
8.61 (2H, dd, J=7.2, 1.2 Hz) ppm; δC (100 MHz, CDCl3) 27.6, 37.9, 
49.4, 122.5, 127.0, 128.1, 131.3, 131.6, 134.1, 164.2 ppm. MS: m/z 303 
(M+Na)+.
Synthesis of 2-(4-azidobutyl)-1H-benzo(de)-isoquinoline-
1,3(2H)-dione (8f): Compound 7f (0.19 g, 0.58 mmol); pale yellow 
solid 7f (93 %); m.p.: 73-75°C; νmax (Nujol) 1650, 2101 cm-1; δH (400 
MHz, CDCl3) 1.70-1.77 (2H, m), 1.80-1.90 (2H, m), 3.36 (2H, t, J=6.8 
Hz), 4.23 (2H, t, J=7.2 Hz), 7.76 (2H, dd, J=8.2, 7.4 Hz), 8.22 (2H, dd, 
J=8.4, 0.8 Hz), 8.60 (2H, dd, J=7.4, 1.0 Hz) ppm; δC (100 MHz, CDCl3) 
25.4, 26.5, 39.6, 51.2, 122.6, 126.9, 128.1, 131.3, 131.6, 134.0, 164.2 ppm. 
MS: m/z 317 (M+Na)+.
Cycloadditions of the azides 8d-f with phenylacetylene 
General procedure: To a solution of compounds 8d-f (0.11-0.28 g, 
0.38-1.05 mmol) in DMF (3-4 mL), was added ascorbic acid (0.1 equiv.), 
copper sulfate (0.01 equiv.) and phenylacetylene (1.3-1.5 equiv.) [16]. 
The reaction mixture was kept stirring at 80°C in an oil bath for 5-24 
h. The reaction mixture was cooled till rt, dichloromethane (15 mL) 
was added, and the resulting solution washed with water (6x10 mL). 
The combined organic phases were dried over magnesium sulfate, 
evaporated in the rotary evaporator to give white or yellow solids. In 
one case the crude product was purified by column chromatography 
(silica, solvent) to give compounds 9d-f (53-95 %).
Synthesis of 2-(2-(4-phenyl-1H-1,2,3-triazol-1-yl)ethyl)-1H-
benzo(de)isoquinoline-1,3(2H)-dione (9d): Compound 8d (0.28 g, 
1.05 mmol); DMF (4 mL); phenylacetylene (1.5 equiv.); 5 h; column 
(DCM:ethanol, 95:5); white solid 9d (56 %); m.p.: 195-199°C; νmax 
(Nujol) 1665, 2100, 3085 cm-1; δH (400 MHz, CDCl3) 4.53 (2H, t, J=5.8 
Hz), 4.75 (2H, t, J=6.0 Hz), 7.30 (1H, t, J=7.4 Hz), 7.40 (2H, t, J=7.6 Hz), 
7.75 (2H, d, J=7.2 Hz), 7.84 (2H, t, J=7.8 Hz), 8.44 (4H, t, J=8.2 Hz), 
8.64 (1H, s) ppm; δC (100 MHz, CDCl3) 39.7, 47.4, 121.8, 122.0, 125.0, 
127.2, 127.4, 127.7, 128.8, 130.8, 130.8, 131.3, 134.5, 146.2, 163.4 ppm. 
HRMS (FAB) calcd for C22H17O2N4: 369.1346 (M+1); found 369.1346.
Synthesis of 2-(3-(4-phenyl-1H-1,2,3-triazol-1-yl)propyl)-1H-
benzo(de)isoquinoline-1,3(2H)-dione (9e): Compound 8e (0.11 g, 
0.40 mmol); DMF (4 mL); phenylacetylene (1.3 equiv.); 12 h; white 
solid 9e (53 %); m.p.: 174-177°C; νmax (Nujol) 1652, 2097, 3081 cm-1; δH 
(400 MHz, CDCl3) 2.48 (2H, quint, J=6.9 Hz), 4.33 (2H, t, J=6.8 Hz), 
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4.55 (2H, t, J=7.0 Hz), 7.32 (1H, t, J=7.4 Hz), 7.41 (2H, t, J=6.8 Hz), 
7.55 (2H, t, J=7.8 Hz), 7.80 (2H, d, J=7.2 Hz), 8.01 (1H, s), 8.16 (2H, dd, 
J=8.4, 0.8 Hz), 8.60 (2H, dd, J=7.4, 1.0 Hz) ppm; δC (100 MHz, CDCl3) 
28.9, 37.6, 48.4, 120.0, 122.3, 125.7, 127.0, 128.0, 128.1, 128.7, 130.5, 
131.4, 131.6, 134.2, 147.6, 164.3 ppm. HRMS (FAB) calcd for C23H19 O2 
N4: 383.1502 (M+1); found 383.1502.
Synthesis of 2-(4-(4-phenyl-1H-1,2,3-triazol-1-yl)butyl)-1H-
benzo(de)isoquinoline-1,3(2H)-dione (9f): Compound 8f (0.11 g, 
0.36 mmol); DMF (3 mL); phenylacetylene (1.5 equiv.); 24 h; yellow 
solid 9f (95 %); m.p.: 137-139°C; νmax (Nujol) 1658, 2096, 3080 cm-1; δH 
(400 MHz, CDCl3) 1.85 (2H, quint, J=7.4 Hz), 2.09 (2H, quint, J=7.4 
Hz), 4.28 (2H, t, J=7.2 Hz), 4.52 (2H, t, J=7.0 Hz), 7.33 (1H, t, J=7.4 Hz), 
7.42 (2H, t, J=7.4 Hz), 7.60 (2H, t, J=7.8 Hz), 7.84 (2H, d, J=7.2 Hz), 
7.89 (1H, s), 8.22 (2H, dd, J=8.2, 1.0 Hz), 8.60 (2H, dd, J=7.2, 1.2 Hz) 
ppm; δC (100 MHz, CDCl3) 25.0, 27.8, 39.2, 49.9, 120.0, 122.4, 125.8, 
127.0, 128.1, 128.8, 130.4, 131.3, 131.3, 131.6, 134.0, 134.1, 164.2 ppm. 
HRMS (FAB) calcd for C24 H21 O2 N4: 397.1659 (M+1); found 397.1651.
Biological activity
Solutions of the compounds: Compound stock solutions were 
prepared in DMSO (Sigma-Aldrich) in a concentration of 1 mM 
and stored at -20°C. Doxorubicin (Sigma-Aldrich) was prepared 
in a stock concentration of 10 mM. All compounds were diluted to 
appropriate concentrations in cell culture medium (RPMI-1640 with 
Ultraglutamine I, Lonza) containing 5% heat-inactivated fetal bovine 
serum (FBS, Biowest) immediately before the assay.
Cell culture: Human tumor cell lines of breast (MCF-7), colorectal 
(HCT-15) and pancreatic (BxPC-3) adenocarcinomas were routinely 
maintained in RPMI-1640 with Ultraglutamine I, supplemented 
with 5% heat-inactivated FBS at 37°C in a humidified atmosphere 
containing 5% CO2. The human leukemia monocyte THP1 cell line 
was differentiated into macrophages by incubating cells in the presence 
of 20 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich) 
for 18h at 37°C in 5% CO2 humidified atmosphere, followed by a 24h 
incubation period in fresh medium with no PMA to induce maturation. 
Mouse bone marrow-derived macrophages (BMMØ) were obtained as 
previously described [17]. Briefly, bone marrow precursors recovered 
from femurs and tibias of Balb/c mice were cultured in complete 
macrophage medium (DMEM medium with glucose (4,5 g/L) (Lonza, 
Switzerland) and HEPES buffer supplemented with 10% FBS, 2 mM 
L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin 
(BioWhittaker, Walkersville, MD), and added of 5% L-929 cell 
conditioned medium (LCCM) as source of macrophage colony-
stimulating factor (M-CSF). After 4h of incubation, non-adherent 
cells were recovered and reseeded in complete medium containing 5% 
LCCM. Fully differentiated macrophages were obtained after 7 days of 
culture with a degree of purity higher than 90%.
Cell growth inhibition assay: The effect of the compounds on the 
growth of three different tumor cell lines, MCF-7, HCT-15 and BxPC-3, 
was evaluated using the sulforhodamine B (SRB, Sigma-Aldrich) assay 
according to the procedure adopted by the National Cancer Institute 
(USA) [18,9]. Briefly, cells were plated in 96-well plates at appropriate 
densities (5×104 cells/ml for MCF-7 and 1×105 cells/ml for HCT-15 
and BxPC-3) and incubated for 24h. Cells were then treated for 48h 
with 5 µM of each compound or with a positive control (doxorubicin), 
fixed with 10% (wt/vol) trichloroacetic acid (TCA, Merck-Millipore), 
and stained with SRB (0.4% wt/vol in 1% acetic acid) for 30min. The 
protein-bound dye was solubilized in 10 mM Tris base solution (Sigma-
Aldrich) and the absorbance measured at 510 nm in a microplate reader 
(Synergy HT - Biotek). The effect of the vehicle solvent (DMSO) on 
the growth of the cells was evaluated by exposing untreated cells to the 
same concentration of DMSO present in the compound solutions used 
in the assay (0.5%). No influence was found (data not shown). A dose-
response curve (serial dilutions of the compounds ranging from 0.313 
µM to 5 µM) and corresponding GI50 (the concentration of compound 
that inhibits growth in 50%) was determined for the most promising 
compounds as described by Monks et al. [20].
Cellular toxicity: The cellular toxicity of the compounds was 
evaluated on THP1 differentiated macrophages and BMMØ using 
the MTT assay. Briefly, cells were cultured in 96 well plates for 72h in 
the presence of the compounds at concentrations of 10 µM for THP1 
differentiated macrophages or 5 µM and 50 µM for BMMØ at 37°C in 
5% CO2. At the end of the incubation period, the culture medium was 
removed and 0.5 mg/ml of MTT reagent (thiazolyl blue tetrazolium 
bromide, Sigma) was added to each well and put to incubate for 4h 
at 37°C. The formazan crystals resulting from the reduction of the 
tetrazolium salt were then solubilized by adding isopropanol and the 
optical density determined at 570 nm corrected for the background 
at 660 nm, using a  micro plate  reader. Results are presented as the 
percentage of viable cells compared with control non-treated cells 
[21,22].
Statistical analysis: All data is presented as mean ± standard error 
(SE). Three to six independent experiments were performed in duplicate 
to determine compounds activity on tumor cells. Cell toxicity assays 
were performed in triplicates in two independent experiments. The data 
was analyzed using two-sided unpaired Student’s t-test. Differences in 
p values below 0.05 were considered statistically significant.
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